



Pierre Fabre

---

**PRESS RELEASE / PRESS RELEASE**  
**For immediate publication**

---

**GENFIT SIGNS A NEW PARTNERSHIP AGREEMENT WITH PIERRE FABRE**

The collaboration between the two groups, initiated in October 2001, is taking on a new dimension with the selection of a new family of compounds for development that is targeting several risk factors of cardiovascular diseases.

**Lille, January 3<sup>rd</sup> 2005** - GENFIT, a biotechnology company active in the discovery and development of drug candidates in the fields of cardiovascular, inflammatory and metabolic diseases, is today announcing the signature of a new partnership deal with the PIERRE FABRE Group.

Both companies have been collaborating since October 2001 on the pharmacological characterization of several products and their mechanisms of action in the field of cardiovascular diseases. The new partnership deal relates to the development of a new family of compounds for which proof of concept has already been obtained.

Employing the full technological know-how mastered by GENFIT in the areas of genomics, proteomics, bioinformatics, *in vitro* and *in vivo* validation, etc., this new 3 years agreement should lead to new therapeutic entities in the field of cardiovascular diseases, with the possibility of acting simultaneously on a variety of different disorders, such as type 2 diabetes, dyslipidemia and atherosclerosis.

Financial terms of this agreement will not be disclosed. The PIERRE FABRE Group will pay GENFIT research fees, milestones and royalties. It will be the intellectual property owner and have exclusive rights to the sale of the products resulting from this agreement.

*"The PIERRE FABRE Group, having invested in a strategy of collaboration with biotechnologies for a long time, has found in GENFIT a high-level partner that will enable it to benefit from unmatched expertise in the field of cardiovascular disease. 'Within this context, it was only natural to renew this fruitful partnership' said Dr. Jacques KUSMIEREK, Chairman of the PIERRE FABRE Research Institute and R&D Director of the PIERRE FABRE Group, before adding "this agreement underlines the commitment of PIERRE FABRE in the cardiovascular field, one of the priority therapeutic directions for the Group's research and development."*

